Pharma Queries - Dr. Brian W. Tempest

Pharma Queries

Dr. Brian W Tempest www.briantempest.com

Beximco

May 14 2014

Hale & Tempest

Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director Far East and Regional Director Middle East & Africa from 1985 to 1992. Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world. He is now Independent Chairman of Religare Capital Markets PLC , a Non Executive Director of Fortis Healthcare the leading Asian Healthcare Company, a Non Executive Director of SRL the largest Indian Diagnostic Company and a Non Executive Director of Glenmark Pharmaceuticals. He is a member of the SCRIP Global awards panel and is on the Editorial Board of the Journal of Generic Medicines. Brian speaks at global conferences and more information on these presentations can be found on his website www.briantempest.com. Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest Co Ltd Hale & Tempest

Nigeria, South Africa & Angola source: Economist 12 April 2014

Hale & Tempest

Factories in Africa source: BWT Research 2013

Hale & Tempest

Evans Medical, Nigeria source: BWT

Mr Olubunmi Olaopa started his career in the industry with Glaxo Nigeria Plc and rose to become the Managing Director of Glaxo Wellcome Nigeria Ltd in 1996. Later when Glaxo Wellcome was merged with SmithKline Beecham Plc in 2000, he was appointed the Managing Director, GlaxoSmithKline (Pharmaceutical) Nigeria & West Africa. He was the Managing Director Cipla Evans Nigeria Ltd before his present appointment as the Group Managing Director of Evans Medical Nigeria Limited.

Professor Elebute (ex Chairman Evans Medical) 15 Maduagwu-Koronu Street Surulere PO Box 8968 LAGOS NIGERIA Hale & Tempest

Angola Market Size source: BWT Research 2014

Overall it is estimated from business contacts that the total size of the Angolan Pharma market is $500m including government tenders. This is estimated to be comprised of a private trade segment of $300m. In addition there is estimated to be a $100m tender market which probably contains many HIV and Malaria medicines. The final $100m is estimated to be the supplies to the private mines and oil fields

Hale & Tempest

French West Africa Markets source: IMS 2010

EUR EUR EUR EUR CMA/2009/07 CMA/2010/07 CUF/2009/07 CUF/2010/07 (Milliers) (Milliers) (Milliers) (Milliers)

Marché sélectionné

43,247

49,040

25,411

29,140

COTE D IVOIRE

11,962

14,032

7,219

8,554

CAMEROUN

6,314

7,051

3,776

4,266

SENEGAL

6,820

7,043

3,715

4,005

MALI

3,475

4,362

1,961

2,445

CONGO

3,697

4,063

2,273

2,401

GABON

3,914

4,042

2,331

2,363

BENIN

2,452

3,088

1,426

1,931

TOGO

1,964

2,203

1,148

1,342

BURKINA FASO

1,915

2,277

1,066

1,323

734

879

496

509

GUINEE

Hale & Tempest

CROs Jordan source: BWT Research 2010

Triumpharma was founded in 2002 with a paid up capital of JD0.1m and currently employs 38 people. The company is now a leading full service regional contract research organisation offering services covering all aspects related to clinical research including phase1,2,3 and 4 clinical trials. The Company has 100 beds and 4 mass spectrometer-HPLC instruments. It is certified by AFSSAPS (2009), USA FDA (2008) and has GMP, GLP and GCP approvals. The clinical trial business is generating a positive cash flow which is partly being invested in a drug delivery development programme where some international patents are now been filed. The greatest obstacle to setting up this business was in the initial funding International Pharmaceutical research Centre (IPRC) was founded in 1994 as a private company with a paid up capital of JD 0.1m and currently employs 100 people. IPRC is a leading full service regional Contract Research Organisation offering service covering most aspects of clinical research. It is certified by the UK MHRA and employs 100 people. Sales reached JD 2.6m in 2008 of which exports are 60%. These successful Clinical Research Organisations are adding to the positive reputation of the Jordanian Healthcare sector and improving the rigor of the technical climate within Jordan. Novartis, Sanofi Aventis and Organon from the big pharma industries have used Jordanian CROs Hale & Tempest

CPhI Russia 137 Companies Source: 17 April 2014

•China 67 •Russia 21 •India 12

•Italy 7 •Czech Republic 5

•Poland, Germany, South Korea 4 •Indonesia, Pakistan, Romania, Latvia, Slovakia, Morocco, Jordan, Spain, Greece, France, Ukraine Hale & Tempest Switzerland, Malaysia 1

[email protected] www.briantempest.com Hale & Tempest